4.8 Article

Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data

Journal

LANCET
Volume 379, Issue 9831, Pages 2053-2062

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(12)60441-3

Keywords

-

Funding

  1. AstraZeneca
  2. Dutch Heart Foundation
  3. Organon
  4. Pfizer
  5. Servier
  6. Netherlands Organisation for Health Research and Development
  7. TNO-Zeist
  8. Boeringher
  9. Schering-Plough
  10. Unilever
  11. National Heart, Lung and Blood Institute (Bethesda, MD, USA)
  12. Pustertaler Verein zur Praevention von Herz- und Hirngefaesserkrankungen
  13. Gesundheitsbezirk Bruneck
  14. Assessorat fuer Gesundheit (Province of Bolzano, Italy)
  15. Stiftung Deutsche Schlaganfall-Hilfe
  16. National Heart, Lung, and Blood Institute [HHSN268201200036C, N01-HC-85239, N01-HC-85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85084, N01-HC-85085, N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, HL080295]
  17. National Institute of Neurological Disorders and Stroke [R37 NS 029993]
  18. National Institute of Dental and Craniofacial Research (Bethesda, MD, USA) [R01 DE 13094]
  19. AOK Bayern
  20. Netherlands Foundation for Scientific Research, ZonMw [Vici 918-76-619]
  21. Federal Ministry of Education and Research (BMBF) [01ZZ9603, 01ZZ0103]
  22. Ministry of Cultural Affairs
  23. Social Ministry of the Federal State of Mecklenburg-West Pomerania
  24. Deutsche Forschungsgemeinschaft (DFG) [Lo 1569/2-1]
  25. MRC [MC_U105260792] Funding Source: UKRI
  26. British Heart Foundation [RG/08/014/24067] Funding Source: researchfish
  27. Medical Research Council [MC_U105260792] Funding Source: researchfish

Ask authors/readers for more resources

Background Carotid intima-media thickness (cIMT) is related to the risk of cardiovascular events in the general population. An association between changes in cIMT and cardiovascular risk is frequently assumed but has rarely been reported. Our aim was to test this association. Methods We identified general population studies that assessed cIMT at least twice and followed up participants for myocardial infarction, stroke, or death. The study teams collaborated in an individual participant data meta-analysis. Excluding individuals with previous myocardial infarction or stroke, we assessed the association between cIMT progression and the risk of cardiovascular events (myocardial infarction, stroke, vascular death, or a combination of these) for each study with Cox regression. The log hazard ratios (HRs) per SD difference were pooled by random effects meta-analysis. Findings Of 21 eligible studies, 16 with 36 984 participants were included. During a mean follow-up of 7.0 years, 1519 myocardial infarctions, 1339 strokes, and 2028 combined endpoints (myocardial infarction, stroke, vascular death) occurred. Yearly cIMT progression was derived from two ultrasound visits 2-7 years (median 4 years) apart. For mean common carotid artery intima-media thickness progression, the overall HR of the combined endpoint was 0.97 (95% CI 0.94-1.00) when adjusted for age, sex, and mean common carotid artery intima-media thickness, and 0.98 (0.95-1.01) when also adjusted for vascular risk factors. Although we detected no associations with cIMT progression in sensitivity analyses, the mean cIMT of the two ultrasound scans was positively and robustly associated with cardiovascular risk (HR for the combined endpoint 1.16, 95% CI 1.10-1.22, adjusted for age, sex, mean common carotid artery intima-media thickness progression, and vascular risk factors). In three studies including 3439 participants who had four ultrasound scans, cIMT progression did not correlate between occassions (reproducibility correlations between r=-0.06 and r=-0.02). Interpretation The association between cIMT progression assessed from two ultrasound scans and cardiovascular risk in the general population remains unproven. No conclusion can be derived for the use of cIMT progression as a surrogate in clinical trials.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available